Abstract
The COVID-19 pandemic death toll now surpasses two million individuals and there is a need for early identification of individuals at increased risk of mortality. Host genetic variation partially drives the immune and biochemical responses to COVID-19 that lead to risk of mortality. We identify and prioritise blood proteins and biomarkers that may indicate increased risk for severe COVID-19, via a proteome Mendelian randomization approach by collecting genome-wide association study (GWAS) summary statistics for >4,000 blood proteins. After multiple testing correction, troponin I3, cardiac type (TNNI3) had the strongest effect (odds ratio (O.R.) of 6.86 per standard deviation increase in protein level), with proteinase 3 (PRTN3) (O.R.=2.48), major histocompatibility complex, class II, DQ alpha 2 (HLA-DQA2) (O.R.=2.29), the C4A-C4B heterodimer (O.R.=1.76) and low-density lipoprotein receptor-related protein associated protein 1 (LRPAP1) (O.R.=1.73) also being associated with higher odds of severe COVID-19. Conversely, major histocompatibility complex class I polypeptide-related sequence A (MHC1A) (O.R.=0.6) and natural cytotoxicity triggering receptor 3 (NCR3) (O.R.=0.46) were associated with lower odds. These proteins are involved in heart muscle contraction, natural killer and antigen presenting cells, and the major histocompatibility complex. Based on these findings, it may be possible to better predict which patients may develop severe COVID-19 and to design better treatments targeting the implicated mechanisms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
COVID-19 Clinical Neuroscience Study is funded by the Medical Research Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB/oversight body is exempted.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and software is publicly available via original sources.
Abbreviations
- C4A
- complement C4A (Rodgers blood group)
- C4B
- complement C4B (Chido blood group)
- CREB3L4
- cAMP responsive element binding protein 3 like 4
- COVID-19
- coronavirus disease 2019
- DEFB119
- beta-defensin 119
- GWAS
- genome-wide association study
- HLA-DQA2
- major histocompatibility complex (MHC), class II, DQ alpha 2
- LRPAP1
- low-density lipoprotein (LDL) receptor-related protein associated protein 1
- MICA
- MHC class I polypeptide-related sequence A
- NCR3
- natural cytotoxicity triggering receptor 3
- OR
- odds ratio
- PRTN3
- proteinase 3
- TNNI3
- troponin I3, cardiac type
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- SE
- standard error
- SNP
- single nucleotide polymorphism
